Xiaolin Wei MD, MPH, PhD
- Email Address(es)
- Office Phone
- 416 978 2020
- Office Address
- 582-155 College Street, Toronto, ON M5T 3M7, Canada
- Clinical Public Health Division
Office of Global Public Health Education & Training
- Associate Professor
- SGS Status
- Associate Member
- Appointment Status
- Global health, focusing on clinical public health interventions in prevention and control of antimicrobial resistance (AMR), tuberculosis (TB), and hypertension and diabetes in low and middle-income countries (LMICs)
- Operations research, randomized controlled trials, cohort studies
- Primary care reform and policy evaluation
Xiaolin is a medical doctor, public health specialists, and the Dalla Lana Chair in Global Health Policy in the University of Toronto. After obtained medical degree and MSc in Public Health in China, he graduated from the Institute of Health Policy, Management and Evaluation at the University of Toronto in 2005. He became a Fellow of the Faculty of Public Health of UK in 2012. Xiaolin has conducted research using implementation science frameworks to change clinical practice and make impacts at the policy level in areas of antimicrobial resistance, tuberculosis control and diabetes/ hypertension care. He also conducted comparative analysis for primary care reforms. He has published nearly 100 high-impact papers in journals such as The Lancet Global Health, Plos Medicine, and WHO Bulletin. As the principle investigator, he has been supported for over $3.7m by CIHR, MRC, DFID, StopTB Partnership and HK RGC. He serves as board member and the Vice President for The International Union of Lung Disease. Before coming to Toronto, he has held faculty positions in the Chinese University of Hong Kong and the University of Leeds, UK.
Education & training history
PhD, University of Toronto, Canada
MPH, Peking University, China
MD (MBBS equivalent), Jining Medical School, China
Fellow, Faculty of Public Health, UK
Vice President, The International Union Against Tuberculosis and Lung Disease
• CHL5631H: Integrating Public Health and Clinical Care: The case of TB (with Dr. Ross Upshur)
• CHL5005H (PhD stream): Introduction to Public Health Research
- HAD5778H: Comparative Health Systems and Policy (with Drs. Greg Marchildon and Sara Allin)
• Supervising Master and PhD students in IHPME and PHS
Current research projects
- Principle investigator: Xiaolin Wei, Jun Hu, Ross Upshur, Improving drug-sensitive TB patients’ treatment adherence through cloud based e-monitors and video observed treatment in Tibet: a randomized controlled trial, 2018-2020, by TB REACH, STOP-TB Partnership, United Nations, US$368,259
- Principle investigator: Xiaolin Wei, Ross Upshur, Frank Sullivan, and France Legare, Promoting treatment supporters for patients who have type 2 diabetes and hypertension: a pilot study, 2017-2019, by Diabetes Action Canada, C$10,000
- Co-investigator: Warren Hugh Dodd, Lincoln Lau, Xiaolin Wei, Donald Cole, S Lee, K Lim, and M Little, Priority setting to address the social determinants of tuberculosis infection and care among income poor households in the Philippines, by Planning and dissemination grant, CIHR, C$20,000
- Wei X, Zhang Z, Hicks JP, Walley JD, King R, Newell JN, et al. Long-term outcomes of an educational intervention to reduce antibiotic prescribing for childhood upper respiratory tract infections in rural China: Follow-up of a cluster-randomised controlled trial. PLoS Med. 2019;16(2):e1002733.
- Zhang Z, Dawkins B, Hicks JP, Walley JD, Hulme C, Elsey H,.. Wei, X. Cost-effectiveness analysis of a multi-dimensional intervention to reduce inappropriate antibiotic prescribing for children with upper respiratory tract infections in China. Tropical medicine & international health : TM & IH. 2018;23(10):1092-100.
- Wei X, Zhang Z, Walley JD, Hicks JP, Zeng J, Deng S, et al. Effect of a training and educational intervention for physicians and caregivers on antibiotic prescribing for upper respiratory tract infections in children at primary care facilities in rural China: a cluster-randomised controlled trial. Lancet Glob Health. 2017;5(12):e1258-e67.
- Ge E, Li D, Luo M, Tsui KWS, Waye MMY, Shen X, Wei X. Transmission of multidrug-resistant tuberculosis in Shanghai: roles of residential status. The international journal of tuberculosis and lung disease. 2018;22(12):1462-8.
- Wei X, Yin J, Walley JD, Zhang Z, Hicks JP, Zhou Y, et al. Impact of China’s essential medicines scheme and zero-mark-up policy on antibiotic prescriptions in county hospitals: a mixed methods study. Tropical medicine & international health : TM & IH. 2017;22(9):1166-74.
- Wei XL, Yin J, Zou GY, Zhang ZT, Walley J, Harwell J, et al. Treatment interruption and directly observed treatment of multidrug-resistant tuberculosis patients in China. The international journal of tuberculosis and lung disease. 2015;19(4):413-9.
- Wei X, Li H, Yang N, Wong SY, Chong MK, Shi L, et al. Changes in the perceived quality of primary care in Shanghai and Shenzhen, China: a difference-in-difference analysis. Bulletin of the World Health Organization. 2015;93:407-16.
- Wei X, Zou G, Walley J, Yin J, Lonnroth K, Uplekar M, et al. China tuberculosis policy at crucial crossroads: comparing the practice of different hospital and tuberculosis control collaboration models using survey data. PloS one. 2014;9(3):e90596.
- Walley J, Graham K, Wei X, Kain K, Weston R. Getting research into practice: primary care management of noncommunicable diseases in low- and middle-income countries. Bulletin of the World Health Organization. 2012;90(6):402.
- Zou G, Wei X, Witter S, Yin J, Walley J, Liu S, et al. Incremental cost-effectiveness of improving treatment results among migrant tuberculosis patients in Shanghai. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2013;17(8):1056-64.
Full publication list available at: https://www.researchgate.net/profile/Xiaolin_Wei2
Google Scholar at: https://scholar.google.com/citations?user=oyiAgloAAAAJ&hl=en